Verve Therapeutics Inc.

07/07/2024 | Press release | Distributed by Public on 07/08/2024 11:05

Potent, Specific, and Durable Liver Editing of PCSK9 in Preclinical Studies of the CRISPR Base Editing Medicine VERVE-101